

**Blenrep (Belantamab Mafodotin-blmf)
Prior Authorization Form**

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Physician billing (HCPCS code: _____) Pharmacy billing (NDC: _____)

Dose: _____ Regimen: _____ Start Date (or date of next dose): _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria

For Initial Authorization

1. Please indicate the diagnosis and information:

Multiple Myeloma

A. Does the member have a diagnosis of relapsed or refractory multiple myeloma?

Yes No

B. Has the member received 4 or more prior therapies? Yes No

i. If yes, please indicate which of the following therapies member has received:

Anti-CD38 monoclonal antibody

Proteasome inhibitor

Immunomodulatory agent

Other: _____

C. Will member receive eye exams, including visual acuity and slit lamp ophthalmic examinations, with each treatment cycle (every 3 weeks)? Yes No

If answer is none of the above, please indicate diagnosis: _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on belantamab mafodotin-blmf?

Yes No

3. Has the member experienced adverse drug reactions related to belantamab mafodotin-blmf therapy?

Yes No

If yes, please specify adverse reactions: _____

Prescriber Signature: _____ Date: _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to **888-601-8461** or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at **AetnaBetterHealth.com/Oklahoma**.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.